Croze Roxanne H, Clegg Dennis O
Center for Stem Cell Biology and Engineering, Center for the Study of Macular Degeneration, Neuroscience Research Institute, Department of Molecular, Cellular and Developmental Biology, University of California, Santa Barbara, Calif., USA.
Dev Ophthalmol. 2014;53:81-96. doi: 10.1159/000357361. Epub 2014 Apr 10.
Ocular diseases affect millions worldwide and dramatically influence the quality of life. Although much is known about ocular biology and disease pathologies, effective treatments are still lacking. The eye is well suited for application of emerging cell-based therapies. This chapter explores the development of stem cell-based treatments for age-related macular degeneration (AMD), a prevalent ocular disease in the elderly. Retinal pigmented epithelium (RPE), a cell type implicated in AMD, has been derived from both induced pluripotent stem cells and embryonic stem cells (ESC). Rapidly advancing research has generated various methods of RPE differentiation and several transplantation strategies. Clinical trials are already underway using suspensions of ESC-derived RPE and others are soon to follow. This chapter will provide an overview of current derivation and transplantation strategies for stem cell-derived RPE for the treatment of AMD and other related ocular diseases.
眼部疾病影响着全球数百万人，并极大地影响生活质量。尽管人们对眼部生物学和疾病病理学了解很多，但仍然缺乏有效的治疗方法。眼睛非常适合应用新兴的基于细胞的疗法。本章探讨了针对年龄相关性黄斑变性（AMD）的基于干细胞的治疗方法的发展，AMD是老年人中一种常见的眼部疾病。视网膜色素上皮（RPE）是一种与AMD相关的细胞类型，已从诱导多能干细胞和胚胎干细胞（ESC）中获得。快速发展的研究已经产生了多种RPE分化方法和几种移植策略。使用ESC来源的RPE悬浮液的临床试验已经在进行中，其他试验也即将开展。本章将概述目前用于治疗AMD和其他相关眼部疾病的干细胞来源RPE的衍生和移植策略。
